Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19689227 | 0.83 | — | — | |
| SCHEMBL18496399 | 0.73 | — | — | |
| SCHEMBL15623308 | 0.73 | — | — | |
| SCHEMBL4527144 | 0.73 | — | — | |
| SCHEMBL5443709 | 0.72 | — | — | |
| SCHEMBL1525327 | 0.72 | KDM1A (0.42) | — | |
| SCHEMBL4526733 | 0.70 | — | — | |
| SCHEMBL9297588 | 0.68 | KMT2A (0.32) | ALDH1A1 | |
| SCHEMBL1524586 | 0.68 | — | — | |
| SCHEMBL9297274 | 0.68 | KMT2A (0.32) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 132 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113677364-B | Pharmaceutical compositions comprising anti-191P 4D12 antibody drug conjugates and methods of use thereof | 艾更斯司股份有限公司 | 2024-07-05 | — | — | CN | disclosed |
| EP-4378482-A2 | DOSING REGIMENS FOR ANTI-CD30 VC-PAB-MMAE ANTIBODY DRUG-CONJUGATES | Seagen Inc. (US) | 2024-06-05 | — | — | EP | disclosed |
| US-20240139275-A1 | WEEKLY DOSING REGIMENS FOR ANTI-CD30 VC-PAB-MMAE ANTIBODY DRUG-CONJUGATES | SEAGEN INC (US) | 2024-05-02 | — | — | US | disclosed |
| US-20240131176-A1 | SYNERGISTIC EFFECTS BETWEEN AURISTATIN-BASED ANTIBODY DRUG CONJUGATES AND INHIBITORS OF THE PI3K-AKT MTOR PATHWAY | SEAGEN INC (US) | 2024-04-25 | — | — | US | disclosed |
| US-20240043556-A1 | ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 158P1D7 PROTEINS | AGENSYS, INC. (US) | 2024-02-08 | — | — | US | disclosed |
| EP-3545969-B1 | DOSING REGIMENS FOR ANTI-CD30 VC-PAB-MMAE ANTIBODY DRUG-CONJUGATES | SEAGEN INC (US) | 2023-12-13 | — | — | EP | disclosed |
| US-20230346968-A1 | ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 191P4D12 PROTEINS | AGENSYS, INC. (US) | 2023-11-02 | — | — | US | disclosed |
| US-20230270871-A1 | MARKERS FOR USE IN METHODS FOR TREATING CANCERS WITH ANTIBODY DRUG CONJUGATES (ADC) | AGENSYS, INC. (US) | 2023-08-31 | — | — | US | disclosed |
| CN-116209464-A | Markers for use in methods of treating cancer with Antibody Drug Conjugates (ADCs) | 艾更斯司股份有限公司 | 2023-06-02 | — | — | CN | disclosed |
| EP-4168039-A1 | MARKERS FOR USE IN METHODS FOR TREATING CANCERS WITH ANTIBODY DRUG CONJUGATES (ADC) | Agensys, Inc. (US) | 2023-04-26 | — | — | EP | disclosed |
| US-20110110936-A1 | ANTI-GCC ANTIBODY MOLECULES AND RELATED COMPOSITIONS AND METHODS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-05-12 | — | — | US | disclosed |
| WO-2011050242-A1 | ANTI-GCC ANTIBODY MOLECULES AND RELATED COMPOSITIONS AND METHODS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-04-28 | — | — | WO | disclosed |
| WO-2011038159-A2 | DR5 LIGAND DRUG CONJUGATES | SEATTLE GENETICS, INC. (US) | 2011-03-31 | — | — | WO | disclosed |
| US-20110070248-A1 | DR5 LIGAND DRUG CONJUGATES | SEATTLE GENETICS, INC. (US) | 2011-03-24 | — | — | US | disclosed |
| US-20100330107-A1 | ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 24P4C12 PROTEINS | AGENSYS, INC. (US) | 2010-12-30 | — | — | US | disclosed |
| WO-2010111018-A1 | ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 24P4C12 PROTEINS | AGENSYS, INC. (US) | 2010-09-30 | — | — | WO | disclosed |
| US-20100215671-A1 | Combination Therapy With Antibody-Drug Conjugates | SEAGEN INC. | 2010-08-26 | — | — | US | disclosed |
| EP-2211885-A1 | COMBINATION THERAPY WITH ANTIBODY-DRUG CONJUGATES | Seattle Genetics, Inc. (US) | 2010-08-04 | — | — | EP | disclosed |
| WO-2010081004-A1 | WEEKLY DOSING REGIMENS FOR ANTI-CD30 VC-PAB-MMAE ANTIBODY DRUG-CONJUGATES | SEATTLE GENETICS, INC. (US) | 2010-07-15 | — | — | WO | disclosed |
| WO-2009048967-A1 | COMBINATION THERAPY WITH ANTIBODY-DRUG CONJUGATES | SEATTLE GENETICS, INC. (US) | 2009-04-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240131176-A1 | SYNERGISTIC EFFECTS BETWEEN AURISTATIN-BASED ANTIBODY DRUG CONJUGATES AND INHIBITORS OF THE PI3K-AKT MTOR PATHWAY | MTOR, RICTOR, PIK3R5 | ALDH1A1 3563/4885ALOX15 4615/4885KDM4E 1696/4885 |
| US-20240043556-A1 | ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 158P1D7 PROTEINS | LGALS3BP, PABPC4, PA2G4 | ALDH1A1 1052/4885ALOX15 4472/4885KDM4E 1927/4885 |
| US-20100330107-A1 | ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 24P4C12 PROTEINS | CD2BP2, IGSF11, PA2G4 | ALDH1A1 1372/4885ALOX15 4458/4885KDM4E 2294/4885 |
| US-20110070248-A1 | DR5 LIGAND DRUG CONJUGATES | TNFRSF1A, TNFSF10, TNFRSF9 | ALDH1A1 2427/4885ALOX15 1497/4885KDM4E 4658/4885 |
| US-20240139275-A1 | WEEKLY DOSING REGIMENS FOR ANTI-CD30 VC-PAB-MMAE ANTIBODY DRUG-CONJUGATES | CD44, PABPC1, CD47 | ALDH1A1 639/4885ALOX15 2793/4885KDM4E 743/4885 |
| US-20100215671-A1 | Combination Therapy With Antibody-Drug Conjugates | BCL6, BCL3, CD22 | ALDH1A1 546/4885ALOX15 4119/4885KDM4E 2224/4885 |
| US-20110110936-A1 | ANTI-GCC ANTIBODY MOLECULES AND RELATED COMPOSITIONS AND METHODS | CD2BP2, UACA, COPG2 | ALDH1A1 4609/4885ALOX15 4549/4885KDM4E 2861/4885 |
| US-20230270871-A1 | MARKERS FOR USE IN METHODS FOR TREATING CANCERS WITH ANTIBODY DRUG CONJUGATES (ADC) | CD44, CD2BP2, EPCAM | ALDH1A1 73/4885ALOX15 4270/4885KDM4E 3625/4885 |
| US-20230346968-A1 | ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 191P4D12 PROTEINS | IGSF11, CD2BP2, PA2G4 | ALDH1A1 801/4885ALOX15 4658/4885KDM4E 2416/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.